SCHEMBL2009386

SCHEMBL2009386

Cc1ccccc1Cc1nsc(N2CCN(CCN)CC2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 3/20 0.47
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
NPSR1 Q6W5P4 1/20 0.39
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36
FAAH O00519 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
CYP2D6 P10635 1/20 0.35
ABCB1 P08183 1/20 0.35
ABCG2 Q9UNQ0 1/20 0.35
TRPC5 Q9UL62 1/20 0.35
HRH4 Q9H3N8 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
TAAR1 Q96RJ0 1/20 0.35
DPP4 P27487 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2006496 0.87 HTR6 (0.47) HTR6KMT2AMEN1NPC1RAB9A
SCHEMBL2007342 0.85 HTR6 (0.50) HTR6KMT2AALDH1A1KDM4ELMNA
SCHEMBL2002360 0.83 SIGMAR1 (0.48) HTR6KMT2AMEN1NPC1RAB9A
SCHEMBL2007843 0.81 CNR1 (0.47) HTR6NPSR1ALDH1A1FAAHSIGMAR1
SCHEMBL2005879 0.80 LMNA (0.47) HTR6KMT2AMEN1NPC1RAB9A
SCHEMBL2006176 0.79 HTR6 (0.49) HTR6ALDH1A1KDM4EFAAHSIGMAR1
SCHEMBL2011056 0.78 ALDH1A1 (0.42) HTR6ALDH1A1SIGMAR1DPP4
SCHEMBL2009208 0.76 LMNA (0.43) HTR6KMT2AMEN1NPC1RAB9A
SCHEMBL2007020 0.76 HTR6 (0.44) HTR6KMT2AMEN1NPC1RAB9A
SCHEMBL2006334 0.76 HTR6 (0.44) HTR6KDM4ELMNASIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US disclosed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US disclosed
EP-2094677-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV Remynd (BE) 2009-09-02 EP disclosed
WO-2008061781-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES SNCA, PARK7, PRNP HTR6 2082/4885KMT2A 3893/4885MEN1 4386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.